ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : CELLULAR THERAPY FOR
Scheme : Project Grants
Australian State/Territory : SA
Clear All
Filter by Field of Research
Cancer Therapy (excl. Chemotherapy and Radiation Therapy) (1)
Clinical Sciences not elsewhere classified (1)
Haematological Tumours (1)
Infectious Diseases (1)
Medical and Health Sciences not elsewhere classified (1)
Nutritional Physiology (1)
Preventive Medicine (1)
Rehabilitation and Therapy (excl. Physiotherapy) (1)
Reproduction (1)
Respiratory Diseases (1)
Solid Tumours (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (11)
Filter by Status
Closed (11)
Filter by Scheme
Project Grants (11)
Filter by Country
Australia (11)
Filter by Australian State/Territory
SA (11)
NSW (2)
QLD (1)
VIC (1)
  • Researchers (0)
  • Funded Activities (11)
  • Organisations (12)
  • Funded Activity

    EGF Peptide Signalling Improves Oocyte Maturation And Quality

    Funder
    National Health and Medical Research Council
    Funding Amount
    $586,891.00
    Summary
    Infertility is common and although IVF is widely accepted, the procedure is expensive and is associated with health risks. Using laboratory animals, we have developed significant new insights into mechanisms regulating egg quality. These insights have allowed us to develop a new approach to infertility treatment - crucially, one that eliminates the need for ovarian hormone therapy used in IVF. This project will investigate the basic mechanisms underlying our new approach to enable safe clinical .... Infertility is common and although IVF is widely accepted, the procedure is expensive and is associated with health risks. Using laboratory animals, we have developed significant new insights into mechanisms regulating egg quality. These insights have allowed us to develop a new approach to infertility treatment - crucially, one that eliminates the need for ovarian hormone therapy used in IVF. This project will investigate the basic mechanisms underlying our new approach to enable safe clinical implementation.
    Read more Read less
    More information
    Funded Activity

    Personalised Medicine Markers Of Anti-EGFR Antibody Therapy In Metastatic Colorectal Cancer: Accelerating Clinical Translation With Collaborative Meta-analyses Based On Individual-participant Data

    Funder
    National Health and Medical Research Council
    Funding Amount
    $300,953.00
    Summary
    When selecting cancer therapy we take into account ‘biomarkers’, biological cancer characteristics that predict treatment success. We will work with an international group, the Advanced Colorectal Cancer Database, to analyse individual patient clinical trial data. We intend to validate biomarkers used to select treatment with cetuximab or panitumumab. Cancer genes called KRAS, NRAS, PTEN, PIK3CA, EREG and BRAF will be examined. Our study will provide best evidence for personalised treatment.
    More information
    Funded Activity

    Pushing AR Toward Better Outcomes In Breast And Prostate Cancers

    Funder
    National Health and Medical Research Council
    Funding Amount
    $998,754.00
    Summary
    Breast and prostate cancers kill >6000 Australians each year. These cancers are strikingly similar, both driven by hormone receptors that have ‘gone bad’. Current therapies aim to eradicate the receptors. While often effective, therapeutic resistance is common and results in fatal disease. We aim to develop new, less toxic treatments that switch receptor behaviour from good to bad, without destroying them. This should improve quality of life, while preventing drug resistance and loss of lives .... Breast and prostate cancers kill >6000 Australians each year. These cancers are strikingly similar, both driven by hormone receptors that have ‘gone bad’. Current therapies aim to eradicate the receptors. While often effective, therapeutic resistance is common and results in fatal disease. We aim to develop new, less toxic treatments that switch receptor behaviour from good to bad, without destroying them. This should improve quality of life, while preventing drug resistance and loss of lives.
    Read more Read less
    More information
    Funded Activity

    Revolutionising The Diagnosis And Monitoring Of CF Lung Disease

    Funder
    National Health and Medical Research Council
    Funding Amount
    $818,391.00
    Summary
    Cystic fibrosis (CF) lung disease starts early in childhood and relentlessly progresses, with early death a common outcome. There is currently no method capable of detecting very early disease onset nor directly assessing the effectiveness of putative treatments. This project will apply our globally unique X-ray imaging tools, which are capable of imaging lung function at any point across the entire lung, for the very early detection of CF and assessment of clinically applicable treatments.
    More information
    Funded Activity

    Exploiting Increased Autophagy In Bronchial Epithelial Cells: A New Therapeutic Approach For Chronic Obstructive Pulmonary Disease (COPD)

    Funder
    National Health and Medical Research Council
    Funding Amount
    $724,161.00
    Summary
    COPD is incurable, a leading cause of death, and new therapies are urgently needed. Autophagy is a cell response to cell stress conditions, however increased autophagy is harmful. We will investigate the association of increased autophagy with COPD and smoking and evaluate therapies that can reduce autophagy, including zinc-related drugs and novel antibiotics that have been modified to lose their anti-bacterial activity.
    More information
    Funded Activity

    A Randomised Controlled Trial (RCT) Of Azithromycin Versus Doxycycline For The Treatment Of Rectal Chlamydia Infection In Men Who Have Sex With Men.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $797,906.00
    Summary
    Rectal chlamydia is very common among gay men; it can exist for long periods without symptoms leading to ongoing transmission. Azithromycin (1 gram single dose) or 7 days doxycycline (100mg twice daily) are the two recommended treatments globally. But, there is concern about rectal chlamydia treatment with reports of up to 22% failure following azithromycin. We will conduct a randomised trial to compare these treatments for rectal chlamydia and determine which drug works better.
    More information
    Funded Activity

    Targeting Sphingosine Kinase 1 To Sensitise Acute Myeloid Leukaemia To BH3 Mimetic Therapy

    Funder
    National Health and Medical Research Council
    Funding Amount
    $670,005.00
    Summary
    Acute Myeloid Leukaemia (AML) patients are currently treated with chemotherapeutics and despite their success at achieving disease remission these responses are often short lived, resulting in relapse and death. We have identified sphingosine kinase 1 as a new drug target in AML. This proposal aims to examine the role of targeting sphingosine kinase 1 in combination with new targeted therapies in patient samples and preclinical mouse models of AML.
    More information
    Funded Activity

    Management Of Breathlessness. Cognitive Behavioural Therapy For People With Chronic Obstructive Pulmonary Disease (BREVE RCT)

    Funder
    National Health and Medical Research Council
    Funding Amount
    $402,875.00
    Summary
    For people with chronic lung disease, breathlessness is common, distressing and difficult to relieve. Pulmonary rehabilitation programs have been demonstrated to improve exercise capacity and quality of life. This study will determine whether changing the way people think about the sensation of breathlessness while completing pulmonary rehabilitation, further reduces distress/anxiety and health service use and improve exercise capacity, disability related to breathlessness and quality of life.
    More information
    Funded Activity

    Treating Insomnia Co-morbid With Obstructive Sleep Apnoea: A Randomized Controlled Clinical Effectiveness Trial.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $600,869.00
    Summary
    Obstructive Sleep Apnoea (OSA) is a common but serious sleep disorder. Continuous positive airways pressure (CPAP) therapy can be very effective in treating OSA. We have found that many patients with OSA also suffer from insomnia, and this can make it hard for them to begin CPAP therapy and hard for them to stick to it. This trial will examine the effect of treating insomnia concurrently with CPAP, with the expectation that overall treatment outcomes will improve.
    More information
    Funded Activity

    A Pragmatic Randomised Clinical Trial Of Nicotine Vaporisers Added To Smoking Cessation Treatment For Priority Populations Living With Comorbidities

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,499,145.00
    Summary
    Smoking is a leading cause of early death for people with certain health conditions because they are more likely to smoke and are also at greater risk of tobacco-related disease. This clinical trial will test whether encouraging people living with Hepatitis C Virus, people on opiate substitution therapy and people living with HIV who smoke to use nicotine vaporisers long-term, in addition to current smoking cessation treatments, will help them to stay abstinent from smoking.
    More information

    Showing 1-10 of 11 Funded Activites

    • 1
    • 2
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback